Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Aug;80(2):437–442. doi: 10.1172/JCI113091

Early posthypoglycemic insulin resistance in man is mainly an effect of beta-adrenergic stimulation.

S Attvall, B M Eriksson, J Fowelin, H von Schenck, I Lager, U Smith
PMCID: PMC442256  PMID: 2886515

Abstract

The insulin effect following hypoglycemia was studied with the euglycemic clamp technique in seven healthy subjects. Following an initial euglycemic clamp hypoglycemia was induced and after glucose recovery a second clamp was performed. Glucose production (Ra) and utilization (Rd) were studied with [3-3H]glucose. Each subject was studied four times; during infusion of placebo, propranolol, somatostatin, and a control study where hypoglycemia was prevented. Hypoglycemia induced an insulin resistance with a lower steady state glucose infusion rate following the hypoglycemia during placebo as compared to the control study (2.5 +/- 0.5 and 4.8 +/- 1.0 mg/kg min, respectively, P less than 0.05). The insulin resistance was due to an attenuated insulin effect on both inhibition of Ra (impaired by 37%) and stimulation of Rd (impaired by 61%). The insulin-antagonistic effect was completely prevented by propranolol but only partly by somatostatin. Thus, early posthypoglycemic insulin resistance (2.5-3.5 h after hypoglycemia) is a sustained effect mainly due to beta-adrenergic stimulation.

Full text

PDF
437

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barbosa J., Johnson S. Severe hypoglycemia during maximized insulin treatment of diabetes in a randomized clinical trial. Diabetes Care. 1983 Jan-Feb;6(1):62–63. doi: 10.2337/diacare.6.1.62. [DOI] [PubMed] [Google Scholar]
  2. Bending J. J., Pickup J. C., Collins A. C., Keen H. Rarity of a marked "dawn phenomenon" in diabetic subjects treated by continuous subcutaneous insulin infusion. Diabetes Care. 1985 Jan-Feb;8(1):28–33. doi: 10.2337/diacare.8.1.28. [DOI] [PubMed] [Google Scholar]
  3. Bolli G. B., Dimitriadis G. D., Pehling G. B., Baker B. A., Haymond M. W., Cryer P. E., Gerich J. E. Abnormal glucose counterregulation after subcutaneous insulin in insulin-dependent diabetes mellitus. N Engl J Med. 1984 Jun 28;310(26):1706–1711. doi: 10.1056/NEJM198406283102605. [DOI] [PubMed] [Google Scholar]
  4. Bolli G. B., Gottesman I. S., Campbell P. J., Haymond M. W., Cryer P. E., Gerich J. E. Glucose counterregulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). N Engl J Med. 1984 Nov 8;311(19):1214–1219. doi: 10.1056/NEJM198411083111904. [DOI] [PubMed] [Google Scholar]
  5. Bratusch-Marrain P. R., Smith D., DeFronzo R. A. The effect of growth hormone on glucose metabolism and insulin secretion in man. J Clin Endocrinol Metab. 1982 Nov;55(5):973–982. doi: 10.1210/jcem-55-5-973. [DOI] [PubMed] [Google Scholar]
  6. Buysschaert M., Marchand E., Ketelslegers J. M., Lambert A. E. Comparison of plasma glucose and plasma free insulin during CSII and intensified conventional insulin therapy. Diabetes Care. 1983 Jan-Feb;6(1):1–5. doi: 10.2337/diacare.6.1.1. [DOI] [PubMed] [Google Scholar]
  7. Clutter W. E., Bier D. M., Shah S. D., Cryer P. E. Epinephrine plasma metabolic clearance rates and physiologic thresholds for metabolic and hemodynamic actions in man. J Clin Invest. 1980 Jul;66(1):94–101. doi: 10.1172/JCI109840. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Cowan J. S., Hetenyi G., Jr Glucoregulatory responses in normal and diabetic dogs recorded by a new tracer method. Metabolism. 1971 Apr;20(4):360–372. doi: 10.1016/0026-0495(71)90098-9. [DOI] [PubMed] [Google Scholar]
  9. DEBODO R. C., STEELE R., ALTSZULER N., DUNN A., BISHOP J. S. ON THE HORMONAL REGULATION OF CARBOHYDRATE METABOLISM; STUDIES WITH C14 GLUCOSE. Recent Prog Horm Res. 1963;19:445–488. [PubMed] [Google Scholar]
  10. De Feo P., Bolli G., Perriello G., De Cosmo S., Compagnucci P., Angeletti G., Santeusanio F., Gerich J. E., Motolese M., Brunetti P. The adrenergic contribution to glucose counterregulation in type I diabetes mellitus. Dependency on A-cell function and mediation through beta 2-adrenergic receptors. Diabetes. 1983 Oct;32(10):887–893. [PubMed] [Google Scholar]
  11. De Feo P., Perriello G., De Cosmo S., Ventura M. M., Campbell P. J., Brunetti P., Gerich J. E., Bolli G. B. Comparison of glucose counterregulation during short-term and prolonged hypoglycemia in normal humans. Diabetes. 1986 May;35(5):563–569. [PubMed] [Google Scholar]
  12. Eriksson B. M. Aluminum foil instead of glass plates for thin-layer chromatography in radioenzymic assay. Clin Chem. 1981 Feb;27(2):341–342. [PubMed] [Google Scholar]
  13. Gale E. A., Kurtz A. B., Tattersall R. B. In search of the Somogyi effect. Lancet. 1980 Aug 9;2(8189):279–282. doi: 10.1016/s0140-6736(80)90233-0. [DOI] [PubMed] [Google Scholar]
  14. Gerich J., Davis J., Lorenzi M., Rizza R., Bohannon N., Karam J., Lewis S., Kaplan R., Schultz T., Cryer P. Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man. Am J Physiol. 1979 Apr;236(4):E380–E385. doi: 10.1152/ajpendo.1979.236.4.E380. [DOI] [PubMed] [Google Scholar]
  15. Green A. Catecholamines inhibit insulin-stimulated glucose transport in adipocytes, in the presence of adenosine deaminase. FEBS Lett. 1983 Feb 21;152(2):261–264. doi: 10.1016/0014-5793(83)80392-5. [DOI] [PubMed] [Google Scholar]
  16. Hamburg S., Hendler R., Sherwin R. S. Influence of small increments of epinephrine on glucose tolerance in normal humans. Ann Intern Med. 1980 Oct;93(4):566–568. doi: 10.7326/0003-4819-93-4-566. [DOI] [PubMed] [Google Scholar]
  17. Kirsch D. M., Baumgarten M., Deufel T., Rinninger F., Kemmler W., Häring H. U. Catecholamine-induced insulin resistance of glucose transport in isolated rat adipocytes. Biochem J. 1983 Dec 15;216(3):737–745. doi: 10.1042/bj2160737. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Kleinbaum J., Shamoon H. Effect of propranolol on delayed glucose recovery after insulin-induced hypoglycemia in normal and diabetic subjects. Diabetes Care. 1984 Mar-Apr;7(2):155–162. doi: 10.2337/diacare.7.2.155. [DOI] [PubMed] [Google Scholar]
  19. Lager I., Attvall S., Eriksson B. M., von Schenk H., Smith U. Studies on the insulin-antagonistic effect of catecholamines in normal man. Evidence for the importance of beta 2-receptors. Diabetologia. 1986 Jul;29(7):409–416. doi: 10.1007/BF00506530. [DOI] [PubMed] [Google Scholar]
  20. Lager I., Blohmé G., Smith U. Effect of cardioselective and non-selective beta-blockade on the hypoglycaemic response in insulin-dependent diabetics. Lancet. 1979 Mar 3;1(8114):458–462. doi: 10.1016/s0140-6736(79)90821-3. [DOI] [PubMed] [Google Scholar]
  21. Lager I., Lönnroth P., von Schenck H., Smith U. Reversal of insulin resistance in type I diabetes after treatment with continuous subcutaneous insulin infusion. Br Med J (Clin Res Ed) 1983 Dec 3;287(6406):1661–1664. doi: 10.1136/bmj.287.6406.1661. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Lager I., von Schenck H., Smith U. Glucagon release and glucose counter-regulation during hypoglycaemia. Modifying effect of the previous glucose level. Acta Endocrinol (Copenh) 1985 Sep;110(1):107–113. doi: 10.1530/acta.0.1100107. [DOI] [PubMed] [Google Scholar]
  23. Lager I., von Schenck H., Smith U. Improved but not normalized glucose counter-regulation during glucagon infusion in Type 1 (insulin-dependent) diabetes. Diabetologia. 1984 May;26(5):337–342. doi: 10.1007/BF00266033. [DOI] [PubMed] [Google Scholar]
  24. Lönnroth P., Smith U. beta-Adrenergic dependent downregulation of insulin binding in rat adipocytes. Biochem Biophys Res Commun. 1983 May 16;112(3):972–979. doi: 10.1016/0006-291x(83)91713-8. [DOI] [PubMed] [Google Scholar]
  25. Lönnroth P., Wesslau C., Stenström G., Tisell L. E., Smith U. Reduced insulin binding to human fat cells following beta-adrenergic stimulation--experimental evidence and studies in patients with a phaeochromocytoma. Diabetologia. 1985 Dec;28(12):901–906. doi: 10.1007/BF00703133. [DOI] [PubMed] [Google Scholar]
  26. Pessin J. E., Gitomer W., Oka Y., Oppenheimer C. L., Czech M. P. beta-Adrenergic regulation of insulin and epidermal growth factor receptors in rat adipocytes. J Biol Chem. 1983 Jun 25;258(12):7386–7394. [PubMed] [Google Scholar]
  27. Popp D. A., Shah S. D., Cryer P. E. Role of epinephrine-mediated beta-adrenergic mechanisms in hypoglycemic glucose counterregulation and posthypoglycemic hyperglycemia in insulin-dependent diabetes mellitus. J Clin Invest. 1982 Feb;69(2):315–326. doi: 10.1172/JCI110455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Popp D. A., Tse T. F., Shah S. D., Clutter W. E., Cryer P. E. Oral propranolol and metoprolol both impair glucose recovery from insulin-induced hypoglycemia in insulin-dependent diabetes mellitus. Diabetes Care. 1984 May-Jun;7(3):243–247. doi: 10.2337/diacare.7.3.243. [DOI] [PubMed] [Google Scholar]
  29. Radziuk J., Norwich K. H., Vranic M. Experimental validation of measurements of glucose turnover in nonsteady state. Am J Physiol. 1978 Jan;234(1):E84–E93. doi: 10.1152/ajpendo.1978.234.1.E84. [DOI] [PubMed] [Google Scholar]
  30. Rizza R. A., Cryer P. E., Gerich J. E. Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia. J Clin Invest. 1979 Jul;64(1):62–71. doi: 10.1172/JCI109464. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Rizza R. A., Mandarino L. J., Gerich J. E. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor detect of insulin action. J Clin Endocrinol Metab. 1982 Jan;54(1):131–138. doi: 10.1210/jcem-54-1-131. [DOI] [PubMed] [Google Scholar]
  32. Rizza R. A., Mandarino L. J., Gerich J. E. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes. 1982 Aug;31(8 Pt 1):663–669. doi: 10.2337/diab.31.8.663. [DOI] [PubMed] [Google Scholar]
  33. SOMOGYI M. Exacerbation of diabetes by excess insulin action. Am J Med. 1959 Feb;26(2):169–191. doi: 10.1016/0002-9343(59)90307-9. [DOI] [PubMed] [Google Scholar]
  34. Santiago J. V., White N. H., Skor D. A., Levandoski L. A., Bier D. M., Cryer P. E. Defective glucose counterregulation limits intensive therapy of diabetes mellitus. Am J Physiol. 1984 Aug;247(2 Pt 1):E215–E220. doi: 10.1152/ajpendo.1984.247.2.E215. [DOI] [PubMed] [Google Scholar]
  35. Smith U., Kuroda M., Simpson I. A. Counter-regulation of insulin-stimulated glucose transport by catecholamines in the isolated rat adipose cell. J Biol Chem. 1984 Jul 25;259(14):8758–8763. [PubMed] [Google Scholar]
  36. Viberti G. C., Keen H., Bloom S. R. Beta blockade and diabetes mellitus: effect of oxprenolol and metoprolol on the metabolic, cardiovascular, and hormonal response to insulin-induced hypoglycemia in normal subjects. Metabolism. 1980 Sep;29(9):866–872. doi: 10.1016/0026-0495(80)90126-2. [DOI] [PubMed] [Google Scholar]
  37. Von Schenck H. Production and characterization of an antiserum against pancreatic glucagon. Clin Chim Acta. 1977 Nov 1;80(3):455–463. doi: 10.1016/0009-8981(77)90138-3. [DOI] [PubMed] [Google Scholar]
  38. White N. H., Skor D. A., Cryer P. E., Levandoski L. A., Bier D. M., Santiago J. V. Identification of type I diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med. 1983 Mar 3;308(9):485–491. doi: 10.1056/NEJM198303033080903. [DOI] [PubMed] [Google Scholar]
  39. von Schenck H., Nilsson O. R. Radioimmunoassay of extracted glucagon compared with three non-extraction assays. Clin Chim Acta. 1981 Jan 22;109(2):183–191. doi: 10.1016/0009-8981(81)90333-8. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES